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survey contained demographic, disease characteristic and health care experience 
variables, which were evaluated as potential predictors of DMD adherence using 
logistic regression, controlling for age and gender. No adjustment was made for 
multiplicity. Results: 969 patients completed the survey; 579 met analysis crite-
ria. High vs. intermediate/low adherers represented 47.7% and 52.3%, respectively. 
Average age for high adherers was 49.1 (SD: 10.9), 81.5% female; intermediate/
low adherers had an average age of 47.3 (SD: 11.4), 87.7% female. Of 149 variables, 
the following were associated with greater odds of high adherence: detailed dis-
cussions with health care professional about “how long the treatment had been 
available” (p= 0.02; OR: 1.47; high 56.8% vs. intermediate/low 47.1%) or “long-term 
safety” (p= 0.01; OR: 1.54; high 54.8% vs. intermediate/low 44.2%); satisfaction with 
DMD (p= 0.04; OR: 1.14; high 5.4 [SD: 1.4] vs. intermediate/low 5.2 [SD: 1.3] ); or 
insurance covered entire cost of DMD (p= 0.01; OR: 1.71; high 23.1% vs. intermedi-
ate/low 15.2%). Results indicating lower odds of high adherence included longer 
duration on current therapy (p< 0.01; OR: 0.99; high 63.2 [SD: 53.5] months vs. inter-
mediate/low 75.9 [SD: 60.0] months) and cost made them “skip a dose” (p< 0.01; 
OR: 0.37; high 5.3% vs. intermediate/low 13.4%) or “not fill or refill a prescription” 
(p< 0.01; OR: 0.43; high 5.3% vs. intermediate/low 12.0%). ConClusions: Patient 
and provider dialogue, patient satisfaction with treatment and health plan benefit 
design aspects may affect DMD adherence.
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objeCtives: Explore how MS DMT-persistence can be modelled, compare model’s 
performance and assess the independent drivers for DMT-persistence. Methods: 
Analysis was based on 1638 DMT uses (1.1. 1991–31.12.2010, time at risk 4009 years) 
in incident MS-patient register from Tampere, Vaasa and Seinäjoki regions, Finland. 
DMT-persistence = DMT end-day - DMT initiation day. Cox, exponential, general-
ized gamma, Gompertz, log-logistic, log-normal, and Weibull regression survival 
models were used to model DMT-persistence. Models were compared based on 
goodness-of-fit statistics (Akaike and Bayesian information criteria). Results: 
Mean follow-up from first MS-symptoms and age at first DMT-initiation were 13 
and 36 years, respectively. 73% of patients were female. Based on the data explo-
ration of all known covariates, three DMT-persistence approaches with different 
interpretations, selected covariates and data needs were modelled: 1] sex, birth 
year, time from symptoms to DMT, age, DMT line (1st, 2nd, 3rd, 4th, 5-7th), DMT 
(interferon-β -1a and -1b, glatiramer acetate, other) at DMT initiation; 2] approach 
1] + Expanded Disability Status Scale (EDSS) at DMT initiation; and 3] approach 2] 
+ DMT-discontinuation reason (pregnancy plan, flu-like symptoms, injection-site 
reactions, ineffectiveness, antibodies, other/unknown). There was no gold stand-
ard survival model for DMT-persistence, and some models accommodated higher 
number of covariates and associated dependencies better. For approaches 1] and 
2] Weibull and for 3] Gompertz model provided the best goodness-of-fit. Based on 
all three models (one per approach 1] –3]) with best goodness-of-fit, higher EDSS 
or higher age at DMT initiation, treatment line (3rd and later), and incidence of 
intolerable adverse events (AE) or ineffectiveness were independently associated 
with shorter DMT persistence. In the approach 3], flu-like symptom and injection 
site AEs had the highest hazard ratio for shorter DMT-persistence. ConClusions: 
AEs, EDSS, age, treatment line and ineffectiveness were strong predictors for DMT-
persistence. Flu-like symptoms and injection site AEs showed the highest hazard 
for DMT-discontinuation.
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objeCtives: To compare 6-month persistence rates among patients initiating the 
oral multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod and 
dimethyl fumarate (DMF). Methods: Our retrospective analysis used mail-order 
pharmacy claims from the US open-source LRx™ database (IMS). Patients with ≥ 1 
fingolimod or DMF prescription (index DMT) between 01-April-2013 and 31-July-
2013 were included. Patients were ≥ 18 years old, naive to fingolimod and DMF, and 
had not received multiple DMTs on the date of the first index DMT claim (index 
date). Prescription records were collected from pharmacies supplying ≥ 1 index 
DMT claim between the index date and the last month of follow-up. Persistence 
was assessed as time from initiating index DMT until discontinuation (gap of ≥ 60 
days), receipt of another DMT or the end of the 6-month follow-up period. The 
risk of and time to index DMT discontinuation was assessed using a Cox propor-
tional hazards model (controlling for age, gender and region) and Kaplan-Meier 
analysis, respectively. Results: The study included 9546 patients (fingolimod: 
n= 1390; DMF: n= 8156). The proportion of patients discontinuing index DMT was 
significantly lower for patients receiving fingolimod (23.3%) versus DMF (36.6%; 
p< 0.0001). The risk of discontinuation was 1.6-fold higher in the DMF cohort ver-
sus the fingolimod cohort (hazard ratio, 95% confidence intervals: 1.58, 1.41-1.77; 
p< 0.0001). Time to discontinuation was significantly longer with fingolimod than 
with DMF (p< 0.0001), resulting in a longer duration of therapy persistence for 
fingolimod versus DMF (mean ± standard deviation: 152±53 days versus 135±62 
days, respectively). Results were similar when discontinuation was defined as a 
gap of ≥ 30 days (p< 0.0001 for all outcomes). ConClusions: This analysis provides 
the first insight into short-term persistence rates with oral DMTs. In a real-world 
setting, the risk of discontinuation over 6 months was lower for patients initiating 
fingolimod versus DMF.
QALY gained. However, SA results indicate that the ICER drops below this threshold 
when most current clinical practice at the cited center is considered. Moreover, SA 
results suggest potential ways to optimize the current clinical pathway in order 
to reduce procedure costs even further.
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bACkgRound: Familial chylomicronemia syndrome (FCS) is a rare genetic dis-
order characterized by deficiency of lipoprotein lipase, causing accumulation of 
chylomicrons. An estimated 0.1-0.2 per 100,000 people has FCS worldwide. FCS 
patients present massively elevated triglyceride levels (typically > 2,000 mg/dL), 
resulting in increased risk of recurring acute pancreatitis. Standard triglyceride 
lowering medications are ineffective for FCS patients, who rely on restrictive 
low fat diet to control their triglyceride. There is limited literature about long-
term progression, the burden of illness or consequences of acute pancreatitis for 
FCS. objeCtives: To estimate long term disease progression, costs and conse-
quences of FCS. Methods: An individual Monte Carlo simulation model was built 
to track disease progression of a cohort of FCS patients with a mean age of 37.8 
years, 60% male, and a mean triglyceride level of 2,741 mg/dL. The model projected 
the number of acute pancreatitis events, mortality and medical costs. Benefits 
of a hypothetical triglyceride reduction intervention were assessed. Results: 
With standard diet control, the average life expectancy of the studied cohort was 
estimated to be 16.45 years. These patients were expected to experience 10.16 
episodes of acute pancreatitis during their lifetime, resulting in 80.7 inpatient days. 
The discounted lifetime cost of acute pancreatitis was projected to be $154,126 
per patient. The cumulative mortality due to acute pancreatitis was estimated to 
be 54.3%. Should an intervention reduce triglyceride levels by 50% in FCS patients, 
the life expectancy would be increased by 3.16 years and 7.72 fewer episodes of 
acute pancreatitis would occur, preventing 61.21 inpatient days and saving 
$118,594 in medical cost. ConClusions: FCS patients are at high risk of life-
threatening and costly acute pancreatitis. Reduction in triglyceride levels has a 
significant impact of morbidity and mortality associated with acute pancreatitis. 
An effective triglyceride lowering intervention could mitigate the consequences 
of FCS significantly.
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objeCtives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease that represents the most common chronic neurological disorder 
in young adults. RRMS often leads to disability and is a major cause of reduced 
working capacity due to neurological diseases. Aim of this study is to investigate 
patients’ working productivity during treatment with natalizumab. Methods: 
RRMS-Patients treated with natalizumab for a maximum of three months prior to 
baseline were eligible for study participation. Patients completed the EQ-5D and 
a questionnaire focused on occupational status, working ability, and days absent 
from work at study start study, after 6 months and 12 months. Socio-demographic 
and clinical data were collected. Primary endpoint was work productivity, which 
is defined as hours worked. To estimate costs and cost offsets due to the therapy 
with natalizumab, an average monetary value per working hour has been calcu-
lated to value productivity monetarily. Results: Preliminary results including 95 
patients after 6 months of therapy show a significant increase in work productivity 
of 84 hours (p= 0.014) for the whole study population compared to baseline. The 
average reduction of days absent from work was 4.8 days compared to baseline. 
The increase in working hours leads to an average change of monetarily valued 
productivity per patient and half-year from 6,550.40€ at baseline to 7,600.35€ after 
6 months for the entire study population. A subgroup analysis has been run on 
the group of employed patients. The working hours increased significantly by 
63h per half-year (p= 0.025). ConClusions: In this study, the preliminary results 
show a significant increase in work productivity, which leads to a significant 
increase in the monetary value of productivity, for RRMS-patients treated with 
natalizumab. An increase in working hours as well as a decrease in days absent 
from work led to an increase in monetarily valued productivity. Study was funded 
by Biogen-Idec.
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objeCtives: Identify predictors of multiple sclerosis (MS) disease-modifying drug 
(DMD) adherence. Methods: A random sample of adult MS patients from the US 
National Health and Wellness Survey or Lightspeed Research panel completed an 
internet survey in Nov/Dec2012. Clinical trial–naïve subjects with relapsing-remit-
ting MS who were on their current DMD for ≥ 4months were included. Adherence 
was measured using the 4-item Morisky Scale. Patients were assigned to ‘high’ 
(negative response to all 4 questions: forget to take, careless at times about tak-
ing, stop if better, stop if worse) or ‘intermediate/low’ (any positive response). The 
